Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165152 | 0.77 | LMNA (0.48) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL20534511 | 0.72 | LMNA (0.62) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL28955974 | 0.67 | ATAD2 (0.47) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL31045621 | 0.66 | LMNA (0.54) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL2552963 | 0.65 | CYP3A4 (0.57) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL2532358 | 0.65 | LMNA (0.53) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL2532356 | 0.65 | LMNA (0.53) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL2532353 | 0.65 | LMNA (0.53) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL1165153 | 0.64 | ALDH1A1 (0.49) | LMNAPOLBALDH1A1CYP1A2MAPT | |
| SCHEMBL18640328 | 0.63 | DPYD (0.47) | LMNAALDH1A1CYP1A2MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-06-26 | — | — | US | disclosed |
| EP-4559906-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC. (JP) | 2025-05-08 | — | — | US | disclosed |
| EP-4491624-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | Astellas Pharma Inc. (JP) | 2025-01-15 | — | — | EP | disclosed |
| WO-2024261257-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024019103-A1 | HETEROCYCLIC COMPOUND THAT ACTS ON G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2024-01-25 | — | — | WO | disclosed |
| WO-2023171781-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | アステラス製薬株式会社 | 2023-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250206751-A1 | HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | LMNA 4047/4885POLB 3785/4885ALDH1A1 2144/4885 |
| US-20250145631-A1 | HETEROCYCLIC COMPOUND ACTING ON G12D MUTANT KRAS PROTEIN | KRAS, NRAS, HRAS | LMNA 4165/4885POLB 3285/4885ALDH1A1 2647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.